share_log

IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics; iX Biopharma to Receive a $9M Upfront Plus Up to $239M in Milestone Payments Plus Royalties

IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics; iX Biopharma to Receive a $9M Upfront Plus Up to $239M in Milestone Payments Plus Royalties

IX Biophma公司説,它與Seelos治療公司達成了獨家許可協議;IX Biophma公司將獲得900萬美元的預付款,最高可達2.39億美元的里程碑付款和特許權使用費
Benzinga Real-time News ·  2021/11/24 18:10

iX Biopharma Ltd (SGX:42C), a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced today that it has, through its subsidiary, entered into an exclusive license agreement with Seelos Therapeutics, Inc ("Seelos") (NASDAQ:SEEL), a company focused on developing novel therapeutics for central nervous systems disorders. Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the "Licensed Products"). iX Biopharma will receive a US$9 million (SGD 12 million1 ) upfront payment to be satisfied in cash and shares2 . iX Biopharma is also eligible for up to US$239 million (SGD 323 million1 ) in milestone payments upon achievement by Seelos of certain development milestones and product sales thresholds. iX Biopharma will also receive double digit percentage royalties on future net sales of any Licensed Product. Seelos will fund all future development, manufacturing and commercialisation of the Licensed Products. Eddy Lee, Chairman and CEO of iX Biopharma, said: "We are delighted to collaborate with Seelos Therapeutics, whose deep insights in ketamine drug development make them an ideal partner to further the development of Wafermine and the other sublingual ketamine products. Licensing our WaferiXbased pharmaceutical drugs to suitable third parties for development and commercialisation is a core strategy to unlock the value of our assets. We are therefore excited that this commercially significant agreement with Seelos is a validation of our ability to deliver on this strategy." "The licensing of the WaferiX drug delivery platform for sublingual ketamine broadens Seelos' ketamine franchise with formulations that we believe will be suitable for both acute and chronic dosing. This should enable us to study additional indications beyond our current focus," said Raj Mehra, Ph.D., Chairman and CEO of Seelos. "The pharmacokinetics, pharmacodynamics and safety profile that has been demonstrated to date suggests a formulation that has the potential of being prescribed with less restrictions than current formulations. Our team is excited to be able to study additional indications with this very innovative technology." 1 USD/SGD conversion rate: 1.35 2 US$3.5 million in cash and US$5.5 million in shares in Seelos (Co. Reg. No: 200405621W)

亞洲網加利福尼亞州聖何塞2月16日電利用其專有舌下給藥技術WaferiX開發創新療法的專業製藥公司IX Biophma Ltd(新加坡證券交易所代碼:42C)今天宣佈,它已通過其子公司與專注於開發治療中樞神經系統疾病的新型療法的Seelos治療公司(以下簡稱“SEELOS”)(納斯達克代碼:SEEL)簽訂了獨家許可協議。根據協議,IX Biophma將向Seelos授權其正在開發的先導藥物Wafermine,一種舌下消旋氯胺酮晶片,以及利用WaferiX技術含有氯胺酮R-和S-對映體的其他產品(“許可產品”)。IX Biophma將獲得900萬美元(1200萬新元1)的預付款,以現金和股票2的形式支付。如果Seelos達到某些開發里程碑和產品銷售門檻,IX Biophma還有資格獲得高達2.39億美元(3.23億新元1)的里程碑付款。IX Biophma還將從未來任何許可產品的淨銷售額中獲得兩位數的百分比版税。Seelos將為特許產品的所有未來開發、製造和商業化提供資金。IX Biophma公司董事長兼首席執行官Eddy Lee表示:“我們很高興能與Seelos治療公司合作。, 他們在氯胺酮藥物開發方面的深刻見解使他們成為進一步開發Wafermine和其他舌下氯胺酮產品的理想合作伙伴。將我們基於WaferiX的藥品授權給合適的第三方進行開發和商業化是釋放我們資產價值的核心戰略。因此,我們感到興奮的是,與Seelos達成的這項具有重大商業意義的協議證實了我們實現這一戰略的能力。“”WaferiX舌下氯胺酮藥物輸送平臺的許可擴大了Seelos的氯胺酮專營權,我們相信這些配方將適用於急性和慢性劑量。這將使我們能夠研究我們目前重點之外的其他適應症,“Seelos公司董事長兼首席執行官Raj Mehra博士説,”迄今為止已經證明的藥代動力學、藥效學和安全性狀況表明,一種可能比目前的處方限制更少的處方。我們的團隊很高興能夠用這項非常創新的技術來研究更多的適應症。“1美元/新元的兑換率:1.352美元現金和550萬美元的Seelos股票(註冊號:200405621W)

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論